News

CLINUVEL
Posted by CLINUVEL
June 20, 2016

CLINUVEL’s SCENESSE® launched in Europe

20 June 2016 First commercial delivery, SCENESSE® approved as standard of care...

Read More
CLINUVEL
Posted by CLINUVEL
May 31, 2016

CLINUVEL added to Nasdaq International Designation

 31 May 2016 CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...

Read More
CLINUVEL
Posted by CLINUVEL
May 17, 2016

SCENESSE® treatment in Europe

17 May 2016 German Porphyria Expert Centres to start distribution of SCENESSE®...

Read More
CLINUVEL
Posted by CLINUVEL
April 29, 2016

Appendix 4C - Q3 FY16

29 April 2016 Enclosed is a copy of the quarterly report for...

Read More
CLINUVEL
Posted by CLINUVEL
April 11, 2016

Form 604

11 April 2016 Enclosed is a notice of change of interests of...

Read More
CLINUVEL
Posted by CLINUVEL
April 4, 2016

CLINUVEL Newsletter - April 2016

4 April 2016 Clinuvel is arriving at a point many of our...

Read More
CLINUVEL
Posted by CLINUVEL
March 23, 2016

NICE Highly Specialised Technology workshop reviews SCENESSE®

23 March 2016 NICE’s technical team invited stakeholders with an interest in...

Read More
CLINUVEL
Posted by CLINUVEL
March 18, 2016

s.708A Notice

18 March 2016 Notice under section 708A(5)(e) of the Corporations Act 2001...

Read More
CLINUVEL
Posted by CLINUVEL
March 18, 2016

Appendix 3B

18 March 2016 Enclosed is a new issue announcement, application for quotation...

Read More
CLINUVEL
Posted by CLINUVEL
March 18, 2016

Form 604

18 March 2016 Enclosed is a Notice of Change of Interests of Substantial...

Read More